At a major nuclear medicine conference in Vienna this week, researchers warned that certain widely used medications could interfere with diagnostic imaging scans, potentially leading to misinterpretation. Until formal guidelines are established, they’re advising imaging...

More than five years after the COVID-19 pandemic began, researchers are still uncovering the long-term consequences of the virus. One of the most unsettling findings is that for many people who lost their sense of...

India’s drug regulator has cleared Ozempic (semaglutide), a once-weekly injectable treatment for Type-2 diabetes, opening doors to a therapy that has transformed diabetes care worldwide and sparked a global weight-loss craze. The approval marks a...

Losing weight is rarely about quick fixes. It’s about patience, discipline, and building habits that last. For Dr. Bhawana Anand, a doctor and entrepreneur, that philosophy helped her shed 27.4 kg over three years, dropping...

What is the breakthrough? For the first time in history, doctors have dramatically slowed the progression of Huntington’s disease through gene therapy. In a groundbreaking clinical trial, researchers at University College London reported that the...

What Happened With the Vaccine Schedule? A federal panel tasked with setting the nation’s childhood vaccine schedule made its first major change under new leadership this week—prompting backlash from public health experts. The Advisory Committee...

A groundbreaking mRNA-based cancer vaccine developed in Russia has shown remarkable results in clinical trials, demonstrating 100% efficacy and safety in shrinking large tumors and eliminating cancer cells. The Enteromix vaccine is now awaiting final...

Health experts in California are sounding the alarm over a silent but deadly threat: Chagas disease, spread by the parasite-carrying “kissing bug.” Researchers estimate that as many as 100,000 people in the state could already...

Quick Summary Artificial sweeteners like aspartame and saccharin may speed up brain ageing by 1.6 years. Study followed 13,000 adults in Brazil for eight years. High consumers saw a 62% faster decline in memory and...

Quick Summary Ecnoglutide, a new GLP-1 receptor agonist, has outperformed dulaglutide in a major clinical trial, showing nearly double the weight loss and equal diabetes control. Unlike existing drugs like Ozempic, it targets a single...